Ilana Rogel has invented novel and patented treatment approach to treat wide range of neurodegenerative diseases and specifically Parkinson and Alzheimer diseases. This novel treatment method is based on short peptides drug administration that enables reset and recovery of neurodegenerative diseases at early and mild stages.
Novel treatment proposed by Ilana Rogel include administration of oligopeptides that influence tau proteins of microtubule as well as mitochondria functioning and mito-nuclear cross talk that influence whole protein synthesis and cellular functioning. It is well known today that in most neurodegenerative diseases there is tau protein hyper-phosphorylation that leads to microtubules dysfunction and further cell degeneration. Therefore our suggested treatment has such huge potential and importance in different neurodegenerative diseases treatment. Taking into account that according to the recent researches tau protein and mitochondria dysfunction can be related to aging, on later stages with approved safety these oligopeptides can be investigated for anti-aging effect.
In order to focus and shorten the primary proof of concept we suggest as a first milestone proving the treatment efficacy on microtubule-associated tau proteins in cell culture. As a next major milestone for neurodegenerative disease treatment proof of concept we suggest clinical trials on. Parkinson disease treatment where clinical and motor signs of diseases are better defined and measurable. After safety and efficacy proof in Parkinson patients, treatment protocols should be developed for other neurodegenerative diseases such as Alzheimer, Multiple sclerosis and ALS.
Ilana Rogel is intuitive scientist and philosopher in a widest meaning of these words. For more than 20 years Ilana intensively work on the research of inner deep laws underlying Big Bang and nuclear physics; cross talk of nuclear and chemical reactions within cells, tissues and organs; connection between soul, consciousness and physical diseases. Based on this outstanding and like nothing on earth deep understanding of matter and disease causality was developed this proposed Parkinson and Alzheimer diseases treatment.
Parkinson treatment proof of concept milestones
Recombinant production in E.coli of novel treatment oligopeptides (95-98% purity, lyophilized form).
Cell culture efficacy proof on microtubule-associated tau proteins.
Safety proof trials on animal models (rodents and pigs according to Israel Health Authorities requirement for Clinical trials approval).
Approval for Clinical trials Phase I on Parkinson patients.
Phase I Clinical tests on Parkinson patients to proof the safety and efficacy (about 12-15 patients).
The Company is currently raising 2.5M$ in order to complete proof of concept in Clinical trials Phase I.
Parkinson disease market
Parkinson's disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. The exact cause of Parkinson's disease is not known. It is largely prevalent among the geriatric population. According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States.
The global Parkinson's disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to register a cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025, according to a report published by Transparency Market Research. GlobalData estimates that drug sales for PD in 2016 were approximately $3.1B. Over the 10-year forecast period, the market is expected to grow to $8.8B at a CAGR of 11.1%.
Alzheimer disease market
Alzheimer’s is a kind of dementia, which affects thinking, behavior, and memory of the patient. The progression of the disease is moderate, and it diminishes neurons associated with the learning part of the cerebrum. It is the most common and the most significant form of dementia (more than 60%), which can be observed in people of age between 65 and over.
The Alzheimer’s Therapeutics Market is expected to reach USD 12.43 Billion by 2026, according to a new report by Reports and Data. GlobalData estimates sales of AD therapeutics in 2016 to have been approximately $3 billion across the seven major markets (7MM), which are the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. By 2026, GlobalData anticipates the AD market will have grown at a strong Compound Annual Growth Rate (CAGR) of 17.5%, reaching sales of $14.8 billion across the 7MM. This is mainly attributed to the growing prevalence of both AD and mild cognitive impairment (MCI) and the rapid uptake of biologics and other novel disease-modifying therapies (DMTs).
Chief Scientist: Ilana Rogel is a intuitive scientist, philosopher, naturopath, expert in nutrition. For more than 20 years Ilana help to different patients and specifically patients having incurable or hardly curable diseases. About 8 years ago Ilana founded Midgalor center where she teaches life changing courses for beginner and advance students explaining deep connection between people's physical health and their emotional and spiritual health, thereby allowing them to make choices that would do better with themselves and their spiritual, emotional and physical health.
Ilana is author of four encyclopedic books:
- On green and grey matter.
- On perfect random order.
- On signs & Letters.
- The Brain Universal and Existential journey across time.
Clarification for the term “Cosmic Science”: The ability to see reality in four dimensions, e.g. the reflection of particles to the left and right of a “virtual” vertical axis, to inspect and draw the reflections while referencing physical particles such as amino acids and chemical elements. This is a state of being that exists, as a potential, in every human mind - a dream state that maintains a full clarity of mind.
CTO and VP R&D: Orna Anna Gribova holds PhD in Computational Neuroscience (Hebrew University of Jerusalem), has 18 years' experience in medical field and drug development taking it from the idea to Clinical trials Phase II. Author of list of patents and scientific publications.
CFO: Liron Rogel – hold MA and BA in economics, has more than 17 years' experience in the field serving last 9 years as Israel Finance Director in Pfizer.